Streetbeat News

Earnings

BX

Investors have shown mixed sentiment in Blackstone (NYSE:BX) options, with equal bullish and bearish positions. Benzinga's options scanner revealed 10 transactions, with a price target range of $110 to $125. Blackstone, a major asset manager with $1.001 trillion AUM, is currently trading at $120.58, down by -1.44%. Analysts have mixed reviews, with an average target price of $132. The company's earnings release is expected in 16 days.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 4:16 pm

ACMR

ACM Research shares have seen an uptick following the company's announcement of an increased revenue outlook for the fiscal year 2023.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 4:15 pm

ACCD

Accolade, Inc. shares have risen following the report of their third-quarter earnings. The positive earnings report has likely contributed to investor optimism, driving the stock price up.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 4:13 pm

CUTR

Cutera, Inc. shares have seen an uptick following the announcement of their preliminary financial guidance for FY23, which surpasses previous revenue estimates.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 4:13 pm

BMEA

Biomea Fusion, Inc. (NASDAQ:BMEA) presented at the 42nd Annual J.P. Morgan Healthcare Conference, highlighting clinical progress and 2024 milestones. The company expects to complete the Phase II COVALENT-111 study for type 2 diabetes and the open label portion of the Phase II COVALENT-112 study for type 1 diabetes in 2024. Biomea Fusion reported positive data from previous trials and has received regulatory clearance to proceed with studies. The company is also advancing its oncology assets, with anticipated completion of dose escalation in studies for liquid and solid tumors, and acute leukemias. Additionally, Biomea Fusion is developing its FUSION™ Platform technology.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 4:04 pm

PRCT

PROCEPT BioRobotics (NASDAQ:PRCT) has been analyzed by four analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $44.5, with a high of $50.00 and a low of $37.00, indicating a slight increase from the previous target of $44.00. Analysts from Wells Fargo and Truist Securities have raised their price targets, while Leerink Partners announced a new target. PROCEPT is a surgical robotics company with a focus on urology, and despite its revenue growth of 72.5%, it faces challenges with a net margin of -70.14% and an ROE of -10.82%.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 4:00 pm

TENB

Tenable Holdings (NASDAQ:TENB) has received mixed analyst ratings over the past quarter, with 10 analysts offering diverse opinions. The average 12-month price target is $49.9, with a high of $60.00 and a low of $41.00, reflecting a 1.96% decrease in sentiment. Analysts from firms like Morgan Stanley, Needham, Piper Sandler, Barclays, Stephens & Co., and Wedbush have adjusted their ratings and price targets. Tenable, a cybersecurity company, has shown a revenue growth rate of 15.26% as of September 30, 2023, but lags behind industry peers and has a net margin of -7.72% and ROE of -4.73%.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 4:00 pm

AZN

AstraZeneca (NASDAQ:AZN) is evaluated against its peers in the Pharmaceuticals industry, revealing it may be undervalued based on its lower P/E, P/B, and P/S ratios compared to the industry average. However, its ROE, EBITDA, gross profit, and revenue growth are below the industry average, indicating potential inefficiencies and challenges in profitability and sales volume growth. AstraZeneca's lower debt-to-equity ratio suggests a stronger financial position with less reliance on debt financing.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 4:00 pm

TTD

Trade Desk (NASDAQ:TTD) has been the subject of analysis by 11 analysts in the last three months, with a mix of bullish and somewhat bullish ratings. The average 12-month price target is now $82.29, down from $97.00. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance, with several lowering their price targets. Trade Desk's financials show strong revenue growth but below-average net margin, ROE, and ROA. The company has a low debt-to-equity ratio, indicating conservative financial management.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 4:00 pm

AVGO

Broadcom Inc (NASDAQ:AVGO) is analyzed against its semiconductor industry peers. With a P/E ratio lower than the industry average, it may be undervalued. However, its high P/B and P/S ratios suggest potential overvaluation relative to book value and sales. Broadcom's ROE is above the industry average, indicating strong returns on equity. Yet, its EBITDA, gross profit, and revenue growth are below industry averages, signaling financial challenges. Broadcom's high debt-to-equity ratio compared to top peers also indicates higher financial risk.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 4:00 pm